Home » Myriad Presents Initial Phase IIa Data for Metastatic Melanoma Agent

Myriad Presents Initial Phase IIa Data for Metastatic Melanoma Agent

November 18, 2009

Myriad Pharmaceuticals, Inc. … announced the presentation of initial clinical data from an ongoing Phase 2a study of Azixa, a microtubule destabilizing agent in stage 4 melanoma patients.
StreetInsider

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Myriad Presents Initial Phase IIa Data for Metastatic Melanoma Agent

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

President Biden Issues Executive Order on U.S. Supply Chain

Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

The Revised ICH E8: A Guide to New Clinical Trial Requirements